China Biologic Products, Inc. (CBPO), the largest non-state owned biopharmaceutical company in China, announced today the reception of approval to list its common stock on the NASDAQ.

CBPO, through its majority-owned subsidiaries, constitutes a fully integrated biologic products company, with plasma collection, R&D, production, development, and commercial operations. With a well-established conduit into China’s top hospitals, the various plasma-based products made by CBPO are vital during medical emergencies, or are used for prevention and treatment.

CBPO expects shares to begin trading on the NASDAQ tomorrow, Wednesday, Dec. 2, retaining the CBPO ticker. CEO of CBPO Mr. Chao Ming Zhao thanked shareholders and staff for helping to achieve what he called a “significant milestone” for the Company, and expressed his great pride in being approved to trade on the NASDAQ.

Mr. Zhao went on to say that he viewed the CBPO’s ascension to the NASDAQ as “validation of our integrity and our commitment to sound corporate governance practices”. Zhao hinted at the potential prospects, such as improvement of “visibility within the investment community”, which would result in increased liquidity and an expansion of the Company’s shareholder base.

CBPO, with its well-known commitment to the highest level of ethical behavior and proven production capability, as evinced by their range of biologic products, is in a key position as China’s largest, privately-held biopharma products company.

The move to NASDAQ will indeed increase CBPO’s access to potential investors and signifies a real maturation of the Company, as it moves towards its goal of becoming China’s top first-class biopharma enterprise.